209 related articles for article (PubMed ID: 35014767)
21. A common mechanism of Sec61 translocon inhibition by small molecules.
Itskanov S; Wang L; Junne T; Sherriff R; Xiao L; Blanchard N; Shi WQ; Forsyth C; Hoepfner D; Spiess M; Park E
Nat Chem Biol; 2023 Sep; 19(9):1063-1071. PubMed ID: 37169959
[TBL] [Abstract][Full Text] [Related]
22. Sec61 blockade by mycolactone inhibits antigen cross-presentation independently of endosome-to-cytosol export.
Grotzke JE; Kozik P; Morel JD; Impens F; Pietrosemoli N; Cresswell P; Amigorena S; Demangel C
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5910-E5919. PubMed ID: 28679634
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4.
Ogbechi J; Hall BS; Sbarrato T; Taunton J; Willis AE; Wek RC; Simmonds RE
Cell Death Dis; 2018 Mar; 9(3):397. PubMed ID: 29540678
[TBL] [Abstract][Full Text] [Related]
24. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Sha Z; Goldberg AL
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
[TBL] [Abstract][Full Text] [Related]
25. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
26. Enhancing ER stress in myeloma.
Wallington-Beddoe CT; Pitson SM
Aging (Albany NY); 2017 Jul; 9(7):1645-1646. PubMed ID: 28758893
[No Abstract] [Full Text] [Related]
27. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N; Hideshima T; Shimomura T; Suzuki R; Ohguchi H; Rizq O; Kikuchi S; Yoshida Y; Cottini F; Jakubikova J; Cirstea D; Gorgun G; Minami J; Tai YT; Richardson PG; Utsugi T; Iwama A; Anderson KC
Cancer Res; 2014 Aug; 74(16):4458-69. PubMed ID: 24934808
[TBL] [Abstract][Full Text] [Related]
28. Mycolactone A vs. B: Multiscale Simulations Reveal the Roles of Localization and Association in Isomer-Specific Toxicity.
Nguyen JDM; da Hora GCA; Swanson JMJ
Toxins (Basel); 2023 Aug; 15(8):. PubMed ID: 37624243
[TBL] [Abstract][Full Text] [Related]
29. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
31. Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
Kambhampati S; Wiita AP
Adv Exp Med Biol; 2020; 1243():147-162. PubMed ID: 32297217
[TBL] [Abstract][Full Text] [Related]
32. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
33. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
35. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
37. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
38. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
39. Mycolactone reveals the substrate-driven complexity of Sec61-dependent transmembrane protein biogenesis.
McKenna M; Simmonds RE; High S
J Cell Sci; 2017 Apr; 130(7):1307-1320. PubMed ID: 28219954
[TBL] [Abstract][Full Text] [Related]
40. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Edwards CM; Lwin ST; Fowler JA; Oyajobi BO; Zhuang J; Bates AL; Mundy GR
Am J Hematol; 2009 May; 84(5):268-72. PubMed ID: 19296472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
